Overcoming
chemotherapy
resistance

Half of all
cancer patients
fail chemotherapy

High unmet medical needs

Overcoming chemotherapy resistance

Our goal at Scandion Oncology is to develop drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is our mission.

Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.

Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.

Read more about us
s

Stay updated with our newsletter

Get notified on mail, when news or press release is posted on our website.

Latest Q&A's

 

Will management and BoD exercise their warrants (TO1) ?

Modified

10.Sep 20

Q: Will management and BoD exercise their warrants (TO1) ?

A: Yes, all management and BoD will all exercise their TO1’s

Timeline on final approval for the pancreatic cancer study?

Modified

08.Sep 20

Q: When do you expect to get the final approval for the pancreatic cancer study ?

 

A: Due to Covid-19 the Ethical Committee is behind. We should have had their response a long time go!!

We expect to have it within few weeks. We can do nothing except calling them frequently.

We initially got a conditional approval but they had a few questions that we immediately responded to. We do not expect that it has to pass their Board again.

Why is a Data Safety Monitoring Board included in the ongoing colorectal cancer study?

Modified

31.Aug 20

Q: How come that you have a Data Safety Monitoring Board (DSMB) in the colorectal cancer study?

 

A: When the aim is to find the Maximal Tolerable Dose a DSMB is always included. According to EMA: EMA´s guideline, #3§ in section 2:

In case of life-threatening diseases usually the implementation of a DMC is indicated from an ethical point of view. This might be regardless of whether the treatment under investigation aims to reduce mortality or morbidity or whether it is intended to relieve the patients’ situation. There are only very rare situations when a DMC might not be considered necessary in such situations. Such a situation arises if a trial can be completed in a very short time, making the use of a DMC not feasible due to practical constraints. However, in case of long-term trials even in non-life-threatening diseases a DMC may be indicated for monitoring safety.

c
More Q/A's

First-in-class cancer treatment

Scandion Oncology will provide new cancer treatments to help overcome chemotherapy resistance for thousands of patients.

Detailed analyses estimate the market to be more than EUR 4 billion annually.

Fast and low-cost track to results

We aim to conclude one Phase II trial within the next two years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Forceful and attractive patents

Scandion Oncology has a forceful patent portfolio lasting until 2037. The patents could be attractive for big pharma to combine with existing cancer treatments.

Pipeline

Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning two Phase II trials within metastatic colorectal cancer and metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.

Investors

Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union